- Home
- QNRX vs QLGN Comparison
QNRX vs QLGN Comparison
Compare QNRX & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- QLGN
- Stock Information
- Founded
- QNRX 2018
- QLGN 1996
- Country
- QNRX United States
- QLGN United States
- Employees
- QNRX N/A
- QLGN N/A
- Industry
- QNRX Medical/Dental Instruments
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- QLGN Health Care
- Exchange
- QNRX Nasdaq
- QLGN Nasdaq
- Market Cap
- QNRX 5.2M
- QLGN 5.8M
- IPO Year
- QNRX N/A
- QLGN N/A
- Fundamental
- Price
- QNRX $15.20
- QLGN $2.82
- Analyst Decision
- QNRX
- QLGN
- Analyst Count
- QNRX 0
- QLGN 0
- Target Price
- QNRX N/A
- QLGN N/A
- AVG Volume (30 Days)
- QNRX 1.0M
- QLGN 3.5M
- Earning Date
- QNRX 11-06-2025
- QLGN 11-14-2025
- Dividend Yield
- QNRX N/A
- QLGN N/A
- EPS Growth
- QNRX N/A
- QLGN N/A
- EPS
- QNRX N/A
- QLGN N/A
- Revenue
- QNRX N/A
- QLGN N/A
- Revenue This Year
- QNRX N/A
- QLGN N/A
- Revenue Next Year
- QNRX N/A
- QLGN N/A
- P/E Ratio
- QNRX N/A
- QLGN N/A
- Revenue Growth
- QNRX N/A
- QLGN N/A
- 52 Week Low
- QNRX $5.01
- QLGN $1.61
- 52 Week High
- QNRX $48.30
- QLGN $8.81
- Technical
- Relative Strength Index (RSI)
- QNRX 62.47
- QLGN 43.97
- Support Level
- QNRX $8.05
- QLGN $2.36
- Resistance Level
- QNRX $14.03
- QLGN $2.85
- Average True Range (ATR)
- QNRX 1.82
- QLGN 0.28
- MACD
- QNRX 0.22
- QLGN 0.00
- Stochastic Oscillator
- QNRX 94.43
- QLGN 44.51
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.